The FDA grants orphan drug designation to Seattle Genetics' (SGEN) Adcetris for the treatment of...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

The FDA grants orphan drug designation to Seattle Genetics' (SGEN) Adcetris for the treatment of mycosis fungoides, the most common form of cutaneous T-cell lymphoma, which is a class of non-Hodgkin's lymphoma. Seattle Genetics is developing Adcetris in combination with Millennium: The Takeda Oncology Company; the drug is in Phase III trials. (PR)